All Search Results
News Releases
Jul 26, 2024, 10:22 ET U.S. FDA Approves LEQSELVI™ (deuruxolitinib), an Oral JAK Inhibitor for the Treatment of Severe Alopecia Areata
company in the U.S. as well as global emerging markets. Sun Pharma's high-growth global specialty portfolio spans innovative products in dermatology, ophthalmology, and onco-dermatology and accounts for over 18% of company sales. The company's vertically integrated operations deliver high-quality medicines,
More news about: Sun Pharmaceutical Industries Limited
Jul 26, 2024, 07:00 ET HanAll Biopharma Reports Q2 2024 Financial Results and Provides Business Update
endocrine, circulatory, and urologic diseases for over 50 years. HanAll has also expanded its focus to immunology, oncology, neurology, and ophthalmology to discover and develop innovative medicines for patients with diseases for which there are no effective treatments. One of its lead pipeline assets,
More news about: HanAll Biopharma
Jul 26, 2024, 06:54 ET Piramal Pharma Limited Announces Consolidated Results for Q1FY25
associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics
More news about: Piramal Pharma Ltd
Jul 26, 2024, 06:45 ET Piramal Pharma Limited Announces Consolidated Results for Q1FY25
associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics
More news about: Piramal Pharma Ltd
Jul 25, 2024, 21:31 ET Innovent and WeComput Announce Strategic Partnership to Advance AI-Driven Drug Discovery and Development
that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, today announced a strategic partnership with WeComput to jointly advance the construction and improvement of Innovent
More news about: Innovent Biologics